This article describes the clinical data that led to approval of these B-cell receptor inhibitors for the treatment of CLL, and highlights newer agents in clinical development that target the same kinases as the currently available therapies.
Deepa Jeyakumar, MD
Advertisement
Articles by Deepa Jeyakumar, MD
Advertisement
Latest Updated Articles
- The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia
Published: November 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
